Literature DB >> 31109863

Medication-related osteonecrosis of the jaw: A literature review.

Shinichiro Kuroshima1, Muneteru Sasaki2, Takashi Sawase3.   

Abstract

BACKGROUND: Antiresorptive agents such as bisphosphonates and denosumab, as well as angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ). However, the exact mechanisms of MRONJ are unclear and definitive treatment strategies have not yet been developed. Moreover, the aging population requiring antiresorptive agents and angiogenesis inhibitors has been increasing worldwide. Therefore, the aim of this literature review was to introduce the latest information on MRONJ. The epidemiology, triggering factors, risk factors, drug holiday, pathoetiology and treatment strategies for each drug-induced ONJ were investigated by conducting a PubMed search. HIGHLIGHT: The prevalence and incidence of ONJ were very low. Some mechanisms of ONJ have been identified, although they were not definitive. Novel treatment strategies have been proposed in basic and clinical research. Several factors, including age and the administration duration of bisphosphonates, are risks for the development of bisphosphonate-related ONJ (BRONJ). Dental implant therapy and peri-implantitis could become risk factors of BRONJ, regardless of the onset timing of bisphosphonates. No reliable information about ONJ induced by denosumab and angiogenesis inhibitors was found.
CONCLUSION: Caution should be taken when dental treatment including implant therapy is performed in patients receiving bisphosphonates, denosumab, and angiogenesis inhibitors. There is limited scientific evidence regarding the relationship between MRONJ and older age. Further ONJ-related research on the aging population is required to manage the treatment of such diseases in older people in the future.
Copyright © 2019 Japanese Association for Oral Biology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis Inhibitors; Antiresorptive Agentst; Bisphosphonates; Denosumab; Osteonecrosis

Mesh:

Substances:

Year:  2019        PMID: 31109863     DOI: 10.1016/j.job.2019.03.005

Source DB:  PubMed          Journal:  J Oral Biosci        ISSN: 1349-0079


  24 in total

1.  Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.

Authors:  Marcelo Vieira da Costa Almeida; Antonio C Moura; Lúcia Santos; Luciana Gominho; Ully Dias Nascimento Távora Cavalcanti; Kaline Romeiro
Journal:  J Lasers Med Sci       Date:  2021-03-08

2.  Research progress on the application of framework nucleic acid in bone regeneration.

Authors:  Yun Feng Lin
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-12-01

Review 3.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

4.  Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.

Authors:  Betul Taş Ozyurtseven; Istemi Serin; Ayse Feyda Nursal; Sacide Pehlivan; Mustafa Pehlivan
Journal:  BMC Oral Health       Date:  2021-05-18       Impact factor: 2.757

5.  Oral Abundance of Actinomyces spp. in Breast Cancer Patients.

Authors:  Ceren Bilgilier; Thorsten Fuereder; Marie-Theres Kastner; Zoltan Vass; Ingeborg Brandl; Hanka Sahbegovic; Christian F Singer; Christoph Steininger
Journal:  Oncology       Date:  2022-01-20       Impact factor: 3.734

6.  Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Siri Paulo; Mafalda Laranjo; Ana M Abrantes; João Casalta-Lopes; Kathleen Santos; Ana C Gonçalves; Anabela Baptista Paula; Carlos Miguel Marto; Ana Bela Sarmento-Ribeiro; Eunice Carrilho; Arménio Serra; Maria F Botelho; Manuel M Ferreira
Journal:  Materials (Basel)       Date:  2019-06-06       Impact factor: 3.623

7.  A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study.

Authors:  Zineb Assili; Gilles Dolivet; Julia Salleron; Claire Griffaton-Tallandier; Claire Egloff-Juras; Bérengère Phulpin
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

8.  Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment.

Authors:  Seung-Hun Lee; So-Young Choi; Min-Su Bae; Tae-Geon Kwon
Journal:  Maxillofac Plast Reconstr Surg       Date:  2021-07-08

Review 9.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

Review 10.  Medication-related Osteonecrosis of the Jaw: A Review.

Authors:  Nouf A AlDhalaan; Asma BaQais; Ahmad Al-Omar
Journal:  Cureus       Date:  2020-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.